Afinitor and Depakene drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Afinitor (everolimus) and Depakene (valproic acid). Common drug interactions include drug ineffective among females and cell marker increased among males.

The phase IV clinical study analyzes what interactions people have when they take Afinitor and Depakene. It is created by eHealthMe based on reports of 34 people who take the same drugs from the FDA, and is updated regularly.

What is Afinitor?

Afinitor has active ingredients of everolimus. It is often used in breast cancer metastatic. eHealthMe is studying from 41,680 Afinitor users. Check the latest studies of Afinitor.

What is Depakene?

Depakene has active ingredients of valproic acid. It is often used in epilepsy. eHealthMe is studying from 14,776 Depakene users. Check the latest studies of Depakene.

On Jul, 27, 2026

34 people who take Afinitor and Depakene together, and have interactions are studied.

Afinitor and Depakene drug interactions.

What are the common drug interactions of Afinitor and Depakene, by gender? *:

female:

Drug ineffective
Dry skin
Hyperglycaemia (high blood sugar)
Pleural effusion (water on the lungs)
Pruritus (severe itching of the skin)
Renal failure chronic (long lasting kidney dysfunction)
White blood cell count increased
Blood glucose increased
Cerebral haemorrhage (bleeding within the brain)
Malignant neoplasm progression (cancer tumour came back)

male:

Cell marker increased
Blood lactate dehydrogenase increased
Hypertriglyceridaemia (excess of triglycerides in the blood)
Stomatitis (inflammation of mucous membrane of mouth)
Blood creatinine increased
Cough
Hypokalaemia (low potassium)
Metastases to liver (cancer spreads to liver)
Renal failure chronic (long lasting kidney dysfunction)
Respiratory distress (difficulty in breathing)

What are the common drug interactions of Afinitor and Depakene, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Blood lactate dehydrogenase increased
Cell marker increased
Lower respiratory tract infection
Status epilepticus (a life-threatening condition in which the brain is in a state of persistent seizure)
Neoplasm progression (growth of tumour)
Neoplasm (tumour)
Abnormal behaviour
Atonic seizures (minor type of seizure)
Insomnia (sleeplessness)
Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)

10-19:

n/a

20-29:

Upper respiratory tract inflammation
White blood cell count decreased
Death
Alanine aminotransferase increased
Aspartate aminotransferase increased
Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
Blood immunoglobulin e increased
Cholecystitis infective (infection of gallbladder capable to infect other organs)
Erythema (redness of the skin)
Erythema of eyelid (redness of the eyelid)

30-39:

Gamma-glutamyltransferase increased
Hypercholesterolaemia (high levels of cholesterol in the blood)
Hyperglycaemia (high blood sugar)
Hypertriglyceridaemia (excess of triglycerides in the blood)
Nasopharyngitis (inflammation of the nasopharynx)
Pruritus (severe itching of the skin)
Pyrexia (fever)
Rash
Stomatitis (inflammation of mucous membrane of mouth)
Somnolence (a state of near-sleep, a strong desire for sleep)

40-49:

n/a

50-59:

Anaemia (lack of blood)
C-reactive protein increased
Haemoglobin decreased
Neoplasm malignant (cancer tumour)

60+:

Weight decreased
Anaemia (lack of blood)
Metastases to liver (cancer spreads to liver)
Pyrexia (fever)
Renal failure chronic (long lasting kidney dysfunction)
Respiratory distress (difficulty in breathing)
Surfactant protein increased
Respiratory failure (inadequate gas exchange by the respiratory system)
Platelet count decreased
Neoplasm malignant (cancer tumour)

What are the existing conditions these people have? *

Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 10 people, 29.41%
Hyperlipidaemia (presence of excess lipids in the blood): 7 people, 20.59%
Tuberous Sclerosis (a rare genetic disease that causes benign tumours to grow in the brain and other organs): 6 people, 17.65%
Insomnia (sleeplessness): 6 people, 17.65%
Renal Cancer Recurrent (cancer of kidney repeat): 3 people, 8.82%
Pancreatic Neuroendocrine Tumor: 3 people, 8.82%
Angiomyolipoma (most common benign tumour of the kidney): 3 people, 8.82%
Renal Cell Carcinoma (a kidney cancer): 2 people, 5.88%
Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 2 people, 5.88%
High Blood Pressure: 2 people, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Afinitor and Depakene?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously